思连康治疗儿童功能性消化不良临床分析

目的探讨思连康治疗儿童功能性消化不良的效果和临床应用安全性。方法采用随机、对照方法，使用思连康治疗3—14周岁患有儿童功能性消化不良症状的患儿各70例。所有参加临床验证的患儿均严格按照人选标准、排除标准选择病例，试验方法和给药方法完全统一。观察日服药物后的起效时间及第6、10天的症状缓解率。结果服药后上腹痛、嗳酸及上腹不适、烧心感症状的半小时缓解率，思连康治疗组优于多酶片对照组，分别为41．42％和11．42％、45．71％和17．14％、35．71％和15．71％（P均〈0．01）。思连康治疗组治疗后的第6天与第10天，临床症状总积分较治疗前显著下降（P〈0．01），有效率分别为80％和75．71％，均高于多酶片对照组（38．57％、48．57％，P均〈0．01），其中上腹痛、上腹不适与烧心症状的改善更为明显。整个疗程中，思连康治疗组未发现任何不良反应。结论思连康对儿童功能性消化不良症状具有显著疗效，本试验期间未观察到任何毒副作用，口味香甜，受到患儿欢迎。

Effect of Bifidobacterium tetravaccine Tablets(live) in the treatment of children with indigestion

Objective To evaluate the efficacy and safety of Bifidobacterium tetravaccine Tablets （live） in the treatment of children with indigestion. Method A randomized and controlled trial was conducted in 140 patients aged from three to fourteen years. They were divided into two groups, each group including 70 children treated with Bifidobaeterium tetravaeeine Tablets （hve） or Multicnzyme Tablets respectively. All the participating patients were strictly selected in accordance with the criteria of selection and exclusion, and the testing methods and instructions discussed before were completely standardized. The time of the efficiency appeared after therapy, the ease of abdominal pain, reflux and abdominal discomfort, heart burning on the sixth and tenth day were recorded. Result The improvement of clinical symptoms （ such as abdominal pain, abdominal discomfort and heart burning） in Bifidobacterium tetravaecine Tablets （llve） group was more sigrtifieant. The remission rate of symptoms （ abdominal pain, reflux and abdominal discomfort, heart burning） within half an hour in Bifidobacterium tetravaceine Tablets （live） group was higher than that in Multicnzyme Tablets group （41.42% versus 11.42%, 45.71% versus 17.14% , 35.71% versus 15.71% ） （ P 〈 0.01 ）. The total score of clinical symptoms in Bitqdobaeterium tetravaceine Tablets （live） group was significantly decreased after 6 days and 10 days treatment （P 〈 0.01 ）, and the response rates on 6th day and 10th day were 80% and 75.71% respectively, higher than those of Multienzyme Tablets group （38.57% and 48.57% ） （P 〈 0.01 ）. And the improvement of abdominal pain, abdominal discomfort and reflux symptoms in Bifidobacterium tetravaecine Tablets （live） group were more obvious. No adverse reaction was found in Bifidobacterium tetravaceine Tablets （live） group. Conclusion Bifidobaeterium tetravaccine Tablets （hve） could be used to treat dyspepsia symptom effectively withut any side-effects. With the sweet taste